【摘要】 目的评价贝那普利联用乐卡地平治疗原发性高血压的疗效和安全性。方法将原发性轻中度高血压患者80例随机分为A组(贝那普利10 mg/乐卡地平10 mg)和B组(贝那普利10 mg)。治疗第4周时坐位舒张压(DBP)仍≥90 mmHg的患者,贝那普利治疗剂量加倍,继续治疗4周,DBP<90 mmHg则维持原剂量,继续治疗4周。结果治疗4周时,A组收缩压(SBP)下降幅度显著大于B组(P<0.05);8周时,A组血压下降幅度显著大于B组(P<0.05)。治疗4、8周时,两组达标率分别为82.1%、59.5%(P<0.05);87.2%、67.6%(P<0.05)。两组不良事件发生率差异无统计学意义。结论贝那普利/乐卡地平联合治疗原发性高血压,可显著降低血压,提高降压达标率,两药联合安全有效。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of benazepril combined with lercanidipine on essential hypertension patients.Methods Eighty patients with mild to moderate essential hypertension were randomized to group A(benazepril 10 mg/L,ercanidiping 10 mg)and group B(benazepril 10 mg).At the end of 4 weeks,the dosage of benazepril in patients with SeDBP≥90 mmHg were doubled for additional 4 weeks,and the patients with SeDBP<90 mmHg remained the initial regimen to 8 weeks.Results Compared with group B,the reduction of blood pressure was significantly greater at the end of 8 weeks in group A(P<0.05),and the reaching target blood pressure rate was better at the end of 4 and 8 weeks(82.1% vs.59.5%,P<0.05;87.2% vs.67.6%,P<0.05).There was no significant difference in adverse events between the two groups.Conclusion Benazepril/lercanidipine combination therapy for essential hypertension was effective in increasing the reaching target blood pressure rate and reducing blood pressure,and was well tolerated by patients.更多还原